ATLANTA, June 26, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Company will webcast its Analyst Day on Wednesday, July 18, 2012 beginning at 10:00 a.m. ET. The meeting will provide an overall update on the company, including additional insight into the ILUVIEN market opportunity in Europe. Presenting from the company will be Dan Myers, Alimera's President and Chief Executive Officer, Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, and Dave Holland, Senior Vice President of Sales and Marketing.
The presentation will be broadcast live over the Internet on the Investor Relations section of the corporate website at http://www.alimerasciences.com, and will be archived online through August 15, 2012.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.